Nuvectis Pharma Financials
| NVCT Stock | USD 4.95 0.15 2.94% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.26 | 2.747 |
|
|
The essential information of the day-to-day investment outlook for Nuvectis Pharma includes many different criteria found on its balance sheet. An individual investor should monitor Nuvectis Pharma's cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Nuvectis Pharma.
Net Income |
|
Nuvectis | Select Account or Indicator |
Understanding current and past Nuvectis Pharma Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Nuvectis Pharma's financial statements are interrelated, with each one affecting the others. For example, an increase in Nuvectis Pharma's assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Nuvectis Pharma's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Nuvectis Pharma. Check Nuvectis Pharma's Beneish M Score to see the likelihood of Nuvectis Pharma's management manipulating its earnings.
Nuvectis Pharma Stock Summary
Nuvectis Pharma competes with Replimune, Lyra Therapeutics, Kronos Bio, Gossamer Bio, and Olema Pharmaceuticals. Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company was incorporated in 2020 and is based in Fort Lee, New Jersey. Nuvectis Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 8 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | US67080T1088 |
| CUSIP | 67080T108 |
| Location | New Jersey; U.S.A |
| Business Address | 1 Bridge Plaza, |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.nuvectis.com |
| Phone | 201 614 3150 |
| Currency | USD - US Dollar |
Nuvectis Pharma Key Financial Ratios
| Return On Equity | -1.4 | ||||
| EBITDA | (22.9 M) | ||||
| Net Income | (22.26 M) | ||||
| Cash Per Share | 0.93 X | ||||
| Current Ratio | 5.20 X |
Nuvectis Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Nuvectis Pharma's current stock value. Our valuation model uses many indicators to compare Nuvectis Pharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Nuvectis Pharma competition to find correlations between indicators driving Nuvectis Pharma's intrinsic value. More Info.Nuvectis Pharma is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . At this time, Nuvectis Pharma's Return On Equity is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Nuvectis Pharma by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Nuvectis Pharma Systematic Risk
Nuvectis Pharma's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Nuvectis Pharma volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twelve with a total number of output elements of fourty-nine. The Beta measures systematic risk based on how returns on Nuvectis Pharma correlated with the market. If Beta is less than 0 Nuvectis Pharma generally moves in the opposite direction as compared to the market. If Nuvectis Pharma Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Nuvectis Pharma is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Nuvectis Pharma is generally in the same direction as the market. If Beta > 1 Nuvectis Pharma moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Nuvectis Pharma Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Nuvectis Pharma's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Nuvectis Pharma growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Nuvectis Pharma November 25, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Nuvectis Pharma help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Nuvectis Pharma. We use our internally-developed statistical techniques to arrive at the intrinsic value of Nuvectis Pharma based on widely used predictive technical indicators. In general, we focus on analyzing Nuvectis Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Nuvectis Pharma's daily price indicators and compare them against related drivers.
| Information Ratio | (0.03) | |||
| Maximum Drawdown | 75.91 | |||
| Value At Risk | (10.50) | |||
| Potential Upside | 10.84 |
Additional Tools for Nuvectis Stock Analysis
When running Nuvectis Pharma's price analysis, check to measure Nuvectis Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nuvectis Pharma is operating at the current time. Most of Nuvectis Pharma's value examination focuses on studying past and present price action to predict the probability of Nuvectis Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nuvectis Pharma's price. Additionally, you may evaluate how the addition of Nuvectis Pharma to your portfolios can decrease your overall portfolio volatility.